Contact hypersensitivity (CHS) is a form of delayed-type hypersensitivity triggered by the response to reactive haptens (sensitization) and subsequent challenge (elicitation). Here, we show that ASK1 promotes CHS and that suppression of ASK1 during the elicitation phase is sufficient to attenuate CHS. ASK1 knockout (KO) mice exhibited impaired 2,4-dinitrofluorobenzene (DNFB)-induced CHS. The suppression of ASK1 activity during the elicitation phase through a chemical genetic approach or a specific inhibitory compound significantly reduced the CHS response to a level similar to that observed in ASK1 KO mice. The reduced response was concomitant with the strong inhibition of production of IL-17, a cytokine that plays an important role in CHS and other inflammatory diseases, from sensitized lymph node cells. These results suggest that ASK1 is relevant to the overall CHS response during the elicitation phase and that ASK1 may be a promising therapeutic target for allergic contact dermatitis and other IL-17-related inflammatory diseases. C ontact hypersensitivity (CHS) is a form of delayed-type hypersensitivity triggered by the response to reactive haptens (sensitization) and subsequent challenge (elicitation) 1 . Clinicians have focused primarily on the latter because it is the phase when allergic contact dermatitis (ACD) is clinically manifested 2 . ACD is one of the most common skin diseases caused by complex immune mechanisms in response to a variety of reactive contact sensitizers, such as metals, preservatives and hair dyes, and is well-modelled by CHS in mice. In the sensitization phase of CHS, epidermal proteins cross-linked with applied haptens are acquired mainly by two populations of dendritic cells (DCs), epidermal Langerhans cells (LCs) and Langerin-positive dermal DCs (dDCs), which have been shown to function redundantly [3] [4] [5] [6] [7] . These DCs migrate to the draining lymph nodes (LNs), where they prime hapten-specific effector T cells. The elicitation phase is initiated by the subsequent challenge of the sensitized animal with the same hapten, which induces infiltration of hapten-primed T cells to the challenge site. The infiltrated T cells subsequently elicit cutaneous inflammation through the production of cytokines such as 9 , the former of which indeed has recently been shown to be critically involved in the regulation of allergic skin diseases, as well as other various inflammatory diseases 10, 11 . Large-scale efforts have been devoted to elucidating the regulatory mechanisms of CHS in the hope of discovering therapeutic targets for ACD.
Contact hypersensitivity (CHS) is a form of delayed-type hypersensitivity triggered by the response to reactive haptens (sensitization) and subsequent challenge (elicitation). Here, we show that ASK1 promotes CHS and that suppression of ASK1 during the elicitation phase is sufficient to attenuate CHS. ASK1 knockout (KO) mice exhibited impaired 2,4-dinitrofluorobenzene (DNFB)-induced CHS. The suppression of ASK1 activity during the elicitation phase through a chemical genetic approach or a specific inhibitory compound significantly reduced the CHS response to a level similar to that observed in ASK1 KO mice. The reduced response was concomitant with the strong inhibition of production of IL-17, a cytokine that plays an important role in CHS and other inflammatory diseases, from sensitized lymph node cells. These results suggest that ASK1 is relevant to the overall CHS response during the elicitation phase and that ASK1 may be a promising therapeutic target for allergic contact dermatitis and other IL-17-related inflammatory diseases. C ontact hypersensitivity (CHS) is a form of delayed-type hypersensitivity triggered by the response to reactive haptens (sensitization) and subsequent challenge (elicitation) 1 . Clinicians have focused primarily on the latter because it is the phase when allergic contact dermatitis (ACD) is clinically manifested 2 . ACD is one of the most common skin diseases caused by complex immune mechanisms in response to a variety of reactive contact sensitizers, such as metals, preservatives and hair dyes, and is well-modelled by CHS in mice. In the sensitization phase of CHS, epidermal proteins cross-linked with applied haptens are acquired mainly by two populations of dendritic cells (DCs), epidermal Langerhans cells (LCs) and Langerin-positive dermal DCs (dDCs), which have been shown to function redundantly [3] [4] [5] [6] [7] . These DCs migrate to the draining lymph nodes (LNs), where they prime hapten-specific effector T cells. The elicitation phase is initiated by the subsequent challenge of the sensitized animal with the same hapten, which induces infiltration of hapten-primed T cells to the challenge site. The infiltrated T cells subsequently elicit cutaneous inflammation through the production of cytokines such as IL-17 and IFN-c 8, 9 , the former of which indeed has recently been shown to be critically involved in the regulation of allergic skin diseases, as well as other various inflammatory diseases 10, 11 . Large-scale efforts have been devoted to elucidating the regulatory mechanisms of CHS in the hope of discovering therapeutic targets for ACD.
Stress-activated p38 mitogen-activated protein kinase (MAPK) signaling has been identified as a mechanism promoting CHS because the pharmacological inhibition of p38 or the heterozygous deletion of the MAPK14 gene that encodes p38a, one of the isoforms of mammalian p38 MAPKs, attenuated the CHS induced by DNFB [12] [13] [14] . The roles of p38 MAPKs in innate immunity are well established, and apoptosis signal-regulating kinase 1 (ASK1), a member of the MAPK kinase kinase (MAP3K) family, is a critical upstream activator of p38 in DCs [15] [16] [17] . However, the mechanism by which p38 promotes CHS and whether or not ASK1 is involved in p38-mediated CHS are not elucidated.
In this study, we found that ASK1 was, as expected, involved in 2,4-dinitrofluorobenzene (DNFB)-induced CHS and that the suppression of ASK1 activity during the elicitation phase through a chemical genetic approach or a specific inhibitory compound significantly attenuated the CHS response, concomitant with the strong inhibition of IL-17 production from sensitized lymph node cells. These results suggest that ASK1 is relevant to the overall CHS response during the elicitation phase.
Results CHS response is attenuated in ASK1 KO mice. To investigate the involvement of ASK1 in CHS, we examined DNFB-induced CHS in ASK1 KO mice and found that it was attenuated compared with that of wild type (WT) mice (Fig. 1A, B) . CHS induced by fluorescein isothiocyanate (FITC) was also attenuated in ASK1 KO mice (Fig. 1C) .
We further examined the role of ASK1 in the regulation of the nature and function of epidermal and dermal DCs. Staining of epidermal sheets with MHC class II antibodies revealed that the morphology and density of LCs were similar between WT and ASK1 KO mice, suggesting that ASK1 was dispensable for the generation and maintenance of LCs (Fig. 1D, E) . FITC was also applied to the skin as a contact sensitizer used to trace DCs, which acquire FITC, migrate to the draining LNs and are detected as FITC-positive cells. At 24 hr after the FITC application to the skin, we isolated the draining LNs and determined the proportion of migrated DCs that was positive for both MHC II and FITC. There was no obvious difference between the WT and ASK1 KO mice, indicating that the FITC-induced migration of DCs to the draining LNs was not affected in the absence of ASK1 (Fig. 1F) . Taken together, ASK1 does not appear to play a major role in epidermal and dermal DCs, at least during the sensitization phase of CHS.
IL-17-producing cells are reduced in ASK1 KO mice. To examine the involvement of ASK1 in lymphocytes, another set of cells important for CHS, we carried out adoptive transfer experiments. Naive ASK1 KO mice transferred with LN cells from DNFBsensitized WT mice did not significantly affect the development of CHS ( Fig. 2A) . In contrast, naive WT mice transferred with LN cells from sensitized ASK1 KO mice showed a significant reduction in ear swelling, suggesting that ASK1 plays a crucial role in lymphocytes in CHS. In the sensitized LNs, hapten-specific T lymphocytes are primed and differentiated, and upon rechallenge with the same hapten, these cells expand and rapidly accumulate in the stimulated site, where they secret proinflammatory cytokines. LN cells from DNFBsensitized WT and ASK1 KO mice proliferated similarly following stimulation with 2,4-dinitrobenzenesulfonic acid (DNBS), a watersoluble compound with the same antigenicity as DNFB (Fig. 2B) ; however, the DNBS-dependent production of IL-17, but not of IFNc, was attenuated in ASK1 KO cells compared with WT cells, suggesting that ASK1 is selectively required for IL-17 production by sensitized LN cells (Fig. 2C) .
At this point, we could not discriminate the roles of ASK1 in the sensitization phase from those in the elicitation phase because in vitro treatment with DNBS somewhat mimics the response of rechallenge with DNFB in the elicitation phase. Therefore, we examined the proportion of IL-17-producing LN cells in the absence of in vitro treatment with DNBS to determine if ASK1 is involved in the differentiation of IL-17-producing cells during sensitization. When the intracellular IFN-c and IL-17 were detected by immunofluorescence in combination with flow cytometric analysis, there was a lower percentage of IL-17-producing LN cells in ASK1 KO mice compared with WT mice, whereas the proportion of IFN-c-positive cells was similar between WT and ASK1 KO mice (Fig. 2D) . A source of IL-17 in CHS is a CD4
1 helper T-cell subset called T-helper 17 (Th17) cells 11 . Because the steroid receptor-type nuclear receptor RORct, which is a splicing variant of RORc, is critical for Th17 differentiation, we examined the expression of RORct mRNA in CD4
1 T cells isolated from sensitized ASK1 KO mice. As shown in Fig. 2E , RORct expression was significantly lower in CD4 1 T cells from ASK1 KO mice than in those from WT mice, whereas expression of other transcription factors such as T-bet, GATA3 and FoxP3, which are critical for the differentiation of Th1 cells, Th2 cells and regulatory T cells, respectively, was not significantly different between WT and ASK1 KO CD4 1 T cells. These results suggest that the attenuation of CHS in ASK1 KO mice is caused, at least in part, by the decreased differentiation of IL-17 cells during sensitization.
Selective suppression of ASK1 activity in the elicitation phase attenuates CHS response. Considering that the reduction of IL-17-producing cells in ASK1 KO mice was not robust (Fig. 2D) , there was a possibility that the decreased differentiation of IL-17 cells during sensitization was not the primary cause of the attenuated CHS response in ASK1 KO mice. To address this issue, we took advantage of a chemical genetic approach, termed analog sensitive kinase allele (ASKA), in which the kinase activity of ASK1 is pharmacologically controlled by the administration of 1Na-PP1, a derivative of the general kinase inhibitor PP1 18 . We first generated cDNA encoding of an ASKA of ASK1 (ASK1 ASKA ) ( Fig. S1 ) and found that the basal activity of the ASK1 ASKA protein, as detected by a phospho-ASK1 antibody that monitors the state of activating phosphorylation of ASK1 19 , was comparable to that of WT ASK1 (Fig. 3A, lanes 1 & 2) . The activity of ASK1 ASKA , but not of WT ASK1, was strongly inhibited by 1Na-PP1, whereas the inhibitory effect of 1NM-PP1, another derivative of PP1, on ASK1 ASKA was marginal (Fig. 3A, lanes 3-10) . We then generated knock-in mice harboring ASK1 ASKA (Fig. 3B) and found that the H 2 O 2 -induced activation of endogenous ASK1 in the absence of 1Na-PP1 was similar in bone marrow-derived macrophages (BMDMs) from homozygous ASK1 ASKA mice and WT mice (Fig. 3C) . We also found that the H 2 O 2 -induced activation of ASK1 was inhibited by 1Na-PP1 in ASK1
ASKA mice in a dose-dependent manner but was not inhibited in WT mice, demonstrating the establishment of a chemical genetic tool suitable for elucidating the biological significance of ASK1 activity in vivo. Interestingly, the selective inhibition of ASK1 activity during elicitation by the administration of 1Na-PP1 to ASK1 ASKA mice strongly suppressed CHS to a level similar to that of ASK1 KO mice [ Fig. 3D , 1Na-PP1 (d5), cf. Fig. 1B] , whereas the administration of 1Na-PP1 during sensitization did not suppress CHS [ Fig. 3D , 1Na-PP1 (d0/1)]. Thus, the inhibition of ASK1 activity during elicitation appeared to be sufficient to suppress CHS. To further examine the requirement of ASK1 activity for CHS in the elicitation phase, we used K811, an inhibitory compound against ASK1 20 . Administration of K811 to WT mice only during elicitation suppressed CHS to a similar extent to that of mice administered K811 during both sensitization and elicitation (Fig. 3E) . Taken together, these results suggest that ASK1 activity in the elicitation phase is more relevant to the overall CHS response than that in the sensitization phase.
ASK1 activity in sensitized CD4
1 T cells is required for IL-17 production. We finally examined the cell type in which ASK1 regulates IL-17 expression. When the LN cells from DNFB-sensitized ASK1 ASKA mice were treated with 1Na-PP1, DNBS-induced activation of ASK1 and the downstream p38 MAPK was detected (Fig. 4A , left panels). The activation of ASK1 and p38 sustained at least until 2 hr after DNBS stimulation and was strongly suppressed by treatment with 1Na-PP1 (Fig. 4A , right panels). Under these experimental conditions, DNBS-induced IL-17 production, but neither DNBS-induced IFN-c production nor cell proliferation, was suppressed by 1Na-PP1 (Fig. 4B-D) , suggesting that ASK1 is required in the elicitation phase for IL-17 production. We have previously shown that ASK1 plays a critical role in the cytokine response to lipopolysaccharide (LPS) in DCs 16 and thus raised the possibility that ASK1 in DCs and/or T cells contributes to IL-17 production. To address this possibility, we isolated CD4
1 T cells and CD11c
1 DCs separately from DNFB-sensitized WT or ASK1 ASKA mice and co-cultured them in vitro in the presence of DNBS. When WT CD4 1 T cells and DCs were reconstituted, DNBSdependent IL-17 production was clearly induced (Fig. 4E) . Intriguingly, 1Na-PP1 suppressed DNBS-induced IL-17 production when ASK1 ASKA CD4 1 T cells and WT CD11c 1 DCs were reconstituted. However, 1Na-PP1 did not suppress IL-17 production upon reconstitution of WT CD4
1 T cells and ASK1 ASKA DCs, suggesting that the ASK1 activity in CD4 1 T cells, rather than that in DCs, is required for the CHS response (Fig. 4F) . Although it has been shown that CD8
1 T cells are also critically involved in the CHS response 21, 22 , selective inhibition of the ASK1 activity in CD8 1 T cells did not affect the DNBS-induced IL-17 production (Fig. 4G) . Taken together, CD4
1 T cells appear to be the primary cells in which ASK1 promotes IL-17 production during CHS.
Discussion
In this study, we showed that ASK1 in the elicitation phase is more relevant to the overall CHS response than that in the sensitization phase, although ASK1 also plays a role in the differentiation of Th17 cells during sensitization. In the elicitation phase, ASK1 in sensitized CD4
1 T cells appears to play a major role in CHS by facilitating IL-17 production, consistent with the reported findings that deficiencies in IL-17 or the IL-17 receptor or the neutralization of IL-17 in WT mice all induce an attenuated CHS response 8, 9, 21 . Whereas the critical involvement of CD8 1 T cells in the elicitation of CHS has been proposed 21, 22 , ASK1 does not appear to be involved in the role of CD8 1 T cells in DNFB-dependent IL-17 production in our reconstitution experiments using CD8
1 T cells and DCs. However, the observed strong attenuation of CHS under ASK1-deficient or ASK1-inactivated conditions still suggest that ASK1 functions not only in CD4
1 T cells but also in CD8 1 T cells, and therefore, this phenomenon requires further investigation.
In CHS models, not only DNFB and FITC that we used in this study, but also oxazolone (Ox) and trinitrochlorobenzene (TNCB), are used as typical haptens 10 . These haptens induce similar responses but probably through different mechanisms. For instance, it has been reported that TNCB-and DNFB-induced, but not Ox-induced, CHS is attenuated in IL-4-deficient mice [23] [24] [25] [26] , whereas CHS induced either by TNCB, DNFB, or Ox is attenuated in IL-17-deficient mice 8, 27 . ASK1 may thus be differently involved in CHS induced by Ox or In addition to the established roles of the ASK1-p38 MAPK pathway in innate immune cells, this study proposes a role for ASK1 in acquired immunity through IL-17 production in lymphocytes. From the viewpoint of IL-17-related diseases, it is intriguing that p38 has been shown to promote IL-17 synthesis in CD4
1 T cells and to be required for the development and progression of experimental allergic encephalomyelitis (EAE), the principal autoimmune model of multiple sclerosis 28 . In the same model, ASK1 KO mice have also been reported to exhibit attenuated inflammatory symptoms 29 , suggesting that the ASK1-p38 MAPK pathway is a key player in various IL-17-related inflammatory diseases. In this study, the ASKA technology constituted a chemical genetic tool that contributed not only to elucidate the phase-specific relevance of ASK1 but also to demonstrate the inhibitory effect of the ASK1 inhibitor K811 on CHS. The combined usage of genetic and chemical tools will be a valuable strategy for the development of ASK1 inhibitors as therapeutic agents against various IL-17-related inflammatory diseases.
Methods
Cell culture, antibodies and reagents. HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 4.5 mg/ml glucose and 100 units/ml penicillin G. A crude population of BMDMs was generated in vitro from mouse bone marrow as described 30 . PE-conjugated antibodies specific for MHC class II (M5/114.15.2), B220 (RA3-6B2) and IL-17 (TC11-18H10) were purchased from BD PharMingen. Phycoerythrin (PE)-Cy5-, PE-, and FITCconjugated antibodies against CD4 (GK1.5) and IFN-c (XMG1.2) were purchased from eBioscience. Phospho-ASK1 antibody that recognizes the activating phosphorylation of ASK1 was described previously 19 . DNFB and DNBS were purchased from Sigma-Aldrich. FITC was purchased from Thermo Scientific. 4-Amino-1-tert-butyl-3-(19-naphthyl)pyrazolo [3,4-d] pyrimidine (1Na-PP1) and 4-amino-1-tert-butyl-3-(19-naphthylmethyl)pyrazolo [3,4-d] pyrimidine (1NM-PP1) were purchased from Calbiochem. The ASK1 inhibitor K811 was provided by Kyowa Hakko Kirin Co., Ltd 20 .
Generation of ASK1
ASKA . We employed the analog-sensitive kinase allele (ASKA) approach 18 to establish a system by which ASK1 activity can be manipulated in vitro and in vivo without affecting the ASK1 protein expression. This aspect is important for the precise investigation of ASK1 because deficiencies of ASK1 proteins have been shown to lead to the degradation of another MAP3K molecule, ASK2, which is stabilized only by forming a heteromeric complex with ASK1 31 . In this approach, a subtle but unique structural distinction between the catalytic domain of one kinase and all other kinases is created by introducing some mutations in the ATP-binding pocket of the kinase, allowing inhibition by ATP analog compounds without affecting the intrinsic kinase activity using native ATP. Based on a variety of successfully established ASKAs reported thus far 32 , two key residues that should be modified in WT kinases to allow the recognition of ATP analogs modified at the N 6 position have been proposed; in the case of murine ASK1, M761 and S828 corresponded to these key residues and were named gatekeeper (GK) and DFG(-1), respectively. In addition, V745, named GK(-16), might be in close contact with the N 6 amino group of bound ATP analogous with CaMKII reported previously 33 . We therefore generated cDNA that encodes ASK1 carrying triple mutations in V745L, M761A and S828A and designated this as ASK1
ASKA . The kinase activity and 1Na-PP1 sensitivity of ASK1 ASKA was evaluated in comparison with ASK1 carrying double mutations (M761A and S828A) as follows: WT ASK1, ASK1 ASKA (V745L/M761A/S828A), or ASK1-M761A/ S828A with a C-terminal V5 epitope tag were expressed in HEK293 cells, and proteins immunoprecipitated with a V5 antibody were subjected to the in vitro kinase assay using recombinant kinase-inactive MKK4 (Merck Millipore) as a substrate as described 34 .
Mice.
A phage genomic DNA library from C57BL/6 mice was screened with a cDNA probe containing exons 15 to 20 of the MAP3K5 gene. vector, in which a neomycin resistance gene cassette flanked by loxP sites was inserted between exons 17 and 18. The linearized targeting vector was electroporated into C57BL/6N-derived CMT2 ES cells. Five out of 3,800 G418-resistant clones were identified by Southern blot analysis with flanking 59 and 39 probes and a neomycin cassette probe followed by confirmation of the three mutations by sequencing the cDNA from each clone. Transient transfection with a Cre recombinase expression vector was used to remove the selection cassette. One of the resulting clones was injected into C57BL/6N blastocysts and passed through the germline of chimeras to generate the ASK1 ASKA mouse line by Merck Serono S.A. Homozygous mutant mice were obtained by F1 heterozygous intercrosses. ASK1 KO mice, in which the ASK1-encoding MAP3K15 gene was homozygously deleted, have been described 30, 35 . The mice were housed in a specific pathogen-free facility. Female mice at 8-10 weeks of age were used for all experiments, which were performed in accordance with protocols approved by the Animal Research Committee of the Graduate School of Pharmaceutical Sciences at the University of Tokyo (Tokyo, Japan).
CHS model. The abdomens of mice were epicutaneously sensitized twice with 25 ml of 0.5% DNFB at a 24-hr interval (days 0 and 1), and the ears were challenged with 20 ml of 0.3% DNFB on day 5. Twenty-four hours later, the ear swelling was measured using a thickness gauge (Mitutoyo) and determined as the difference between the ear thickness of the DNFB-treated side and the vehicle-treated side of the same mouse. For FITC-induced CHS, 400 ml of 0.2% FITC in 151 acetone/dibutylphthalate (Ac/ DBP) was applied to the shaved abdominal skin, and the mice were challenged with 20 ml 0.2% FITC/Ac/DBP on day 6. For the adoptive transfers, 5 3 10 6 LN cells isolated from the LNs of WT or ASK1 KO mice sensitized with DNFB for 5 days were injected intravenously into naive WT or ASK1 KO mice. The ear was immediately challenged with DNFB, and its thickness was measured 48 hr later. For ASK1 ASKA mice, 1Na-PP1 (476.1 ng per g) or the vehicle was injected intravenously. K811 was administered orally at a dose of 100 mg/kg per day as described 20 .
Histology and immunohistochemistry. For morphological analysis of the DNFBinduced CHS response, the mice were killed at day 6, and sections (6 mm) of freshfrozen ear were stained with hematoxylin and eosin. The FITC-based migration assay was performed as described 36 . Briefly, 24 hr after the application of 25 ml of 1% FITC in acetone/dibutyl phthalate to the pre-shaved arm or flank, the brachial and inguinal LNs were analyzed morphologically, and the isolated LN cells were stained with an antibody against MHC class II before flow cytometric analysis using a FACSCaliber (BD Biosciences). For observation of LCs, the ears were excised and placed in dishes containing 250 units/ml of dispase (Godoshusei) in PBS overnight at 4uC. The epidermal sheets were peeled from the underlying dermis and stained with an MHC class II antibody. The numbers of MHC class II-positive cells were counted in random fields for each sheet and used to calculate the LC density.
Proliferation and cytokine assays. Single-cell suspensions (1 3 10 6 cells/ml RPMI 1640 medium containing 10% FBS) prepared from the inguinal and axillary LNs of mice sensitized with DNFB for 5 days were cultured in the presence or absence of 100 mg/ml DNBS for 3 days. The relative cell numbers were determined as the relative fluorescence intensity using a Cell Counting Kit-F (Dojindo). The amounts of IFN-c and IL-17 in the culture supernatants were measured using Quantikine ELISAs according to the manufacturer's instructions (R&D Systems). For the reconstitution assay, CD4 /well) purified from DNFB-sensitized mice using the MACS system (Miltenyi Biotec; purity: .95% and 70%, respectively) were co-cultured in the presence of 100 mg/ml DNBS for 24 hr, and the amounts of IFN-c or IL-17 in the culture supernatants were measured. For the measurement of the proportion of IFN-c-or IL-17-producing cells among all LN cells, the cells were stained with FITC-conjugated IFN-c and PE-conjugated IL-17 antibodies using a Mouse Intracellular Cytokine Staining Starter Kit according to the manufacturer's instructions (BD Biosciences) and were analyzed by flow cytometry.
Quantification of mRNA expression. Total RNA was isolated from CD4 1 T cells purified from draining LN cells using ISOGEN (Nippon Gene) and reversetranscribed with the QuantiTect Reverse Transcription Kit (Qiagen). Quantitative PCR was performed with SYBR Green PCR Master Mix using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). To normalize the relative expression of T-bet, GATA3, RORct and Foxp3 to the GAPDH control, standard curves were prepared for GAPDH and for each gene in each experiment.
Immunoblot analysis. The cells were lysed with a buffer containing 50 mM TrisHCl, pH 8.0, 150 mM NaCl, 1% deoxycholate, 1% Triton X-100, 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride and 5 mg/ml aprotinin. The lysates were resolved by SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes. After blocking with 5% skim milk in TBS-T (50 mM Tris-HCl, pH 8.0, 150 mM NaCl and 0.05% Tween 20), the membranes were probed with antibodies. The antibody/antigen complexes were detected using the ECL system (GE Healthcare).
Statistical analyses. Student's t-test (unpaired, two-tailed) was used to compare two groups of independent samples.
